Today: 27 February 2026
Subscribe
Browse Category

LSE:GSK 27 January 2026 - 27 February 2026

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK shares rose 0.74% to 2,183 pence by 0855 GMT after Japan and China accepted regulatory filings for two experimental liver-disease drugs. The company also agreed to buy Canada’s 35Pharma for $950 million, adding a pulmonary hypertension asset. GSK closed down 2.12% the previous session. Investors await first-quarter results on April 29.
27 February 2026
··
GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK agreed to buy Canada’s 35Pharma for $950 million in cash, adding experimental pulmonary hypertension drug HS235 to its pipeline. GSK shares rose 0.1% to 2,204 pence in early London trading. The deal is subject to regulatory approval in the U.S. and Canada. GSK also reported buying back 462,000 shares as part of its ongoing share repurchase program.
25 February 2026
·
GSK stock price today: shares tick up as buyback rolls on and Global Counsel fallout hits the tape

GSK stock price today: shares tick up as buyback rolls on and Global Counsel fallout hits the tape

GSK shares rose 0.4% to 2,234 pence in early London trading Friday. The company said it would cut ties with Global Counsel, which is entering administration after disclosures about co-founder Peter Mandelson’s past links to Jeffrey Epstein. GSK also disclosed a 410,000-share buyback and a £204,048.58 cash award for Chief Scientific Officer Tony Wood. The quarterly dividend record date is Feb. 20.
20 February 2026
··
GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK shares fell 0.4% in early London trading Thursday after the company released new real-world data on its RSV vaccine Arexvy and the stock went ex-dividend. A U.S. study linked Arexvy to reduced RSV-related hospitalisations and lower rates of major cardiovascular events in adults over 60. GSK also bought back 420,000 shares on Feb. 17. Investors await further RSV data and updates on dividends.
19 February 2026
····
GSK share price dips at London open after 52-week high — what investors watch next

GSK share price dips at London open after 52-week high — what investors watch next

GSK shares fell 0.8% to 2,162 pence in early London trading Friday, retreating from multi-decade highs after a post-earnings rally. The company forecast 2026 turnover growth of 3% to 5%, with currency effects expected to cut reported growth by about 3%. GSK announced a 70 pence dividend target for 2026 and completed £1.4 billion of a £2 billion buyback. President David Redfern sold 100,000 shares at £21.09 each.
6 February 2026
·
FTSE 100 slips from highs as Bank of England looms; Shell results hit UK shares today

FTSE 100 slips from highs as Bank of England looms; Shell results hit UK shares today

UK stocks slipped Thursday, with the FTSE 100 down 0.2% to 10,382 by 1052 GMT as investors awaited the Bank of England’s rate decision. Shell fell 1.9% after missing profit forecasts but kept its buyback pace. Vodafone dropped 4.7% after launching a €500 million buyback. The STOXX 600 lost 0.5% amid mixed European earnings.
5 February 2026
·······
GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK shares surged 6.9% Wednesday to a 25-year high after reporting 2025 sales of £32.7 billion and raising its 2026 outlook. The company projects 2026 revenue growth of 3%–5% and expects core profit and earnings per share to rise 7%–9%. Investors remain cautious about slower growth and looming patent expirations. London markets await Thursday’s open for further reaction.
5 February 2026
··
FTSE 100 breaks 10,400 as Zurich-Beazley bid and GSK lift UK stocks ahead of BoE

FTSE 100 breaks 10,400 as Zurich-Beazley bid and GSK lift UK stocks ahead of BoE

FTSE 100 rose 1.0% to 10,418.51 by mid-morning Wednesday, with Beazley shares jumping nearly 9% after Zurich raised its takeover bid. GSK gained 2.3% on a positive long-term outlook. AI-linked stocks like RELX and LSEG fell again after recent tech sector jitters. Sterling hit a five-month high against the euro ahead of the Bank of England’s rate decision.
4 February 2026
·····
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK shares rose 1.4% Wednesday morning after new CEO Luke Miels issued a 2026 outlook projecting slower sales growth and warning of possible weakness in vaccines and general medicines. The company reported 2025 sales up 7% to £32.67 billion and forecast 2026 turnover growth of 3% to 5%. Investors remain focused on GSK’s ability to manage looming HIV patent expirations.
4 February 2026
···
GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
3 February 2026
····
GSK share price rises into earnings week — what traders watch before Feb 4 results

GSK share price rises into earnings week — what traders watch before Feb 4 results

GSK shares closed Friday up 1.3% at 1,876.5 pence, with 8.9 million shares traded. The company will report fourth-quarter and full-year results on Feb. 4, with consensus forecasts at £8.5 billion core turnover and 23p core EPS. Investors are watching Shingrix, Arexvy, and HIV drug sales. The FTSE 100 rose for a seventh straight month as the pound weakened.
1 February 2026
··
GSK stock price ends week higher as Feb 4 earnings loom — what investors watch next

GSK stock price ends week higher as Feb 4 earnings loom — what investors watch next

GSK shares rose 1.3% to 1,876.5 pence in London on Friday, extending a two-day rally ahead of fourth-quarter results due Feb. 4. Investors are watching for 2026 guidance and updates on vaccine and specialty drug demand. The stock remains about 9% below its December high. GSK recently agreed to buy RAPT Therapeutics for $2.2 billion and signaled changes in its HIV joint venture.
31 January 2026
··
GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares rose 0.34% to 1,823.75 pence early Thursday in London after a 2.42% drop Wednesday. Citi began coverage with a Neutral rating and a 1,900p target, noting pipeline improvements but warning on valuation. Investors await GSK’s Feb. 4 earnings for updates on vaccines, HIV treatments, and 2026 guidance. GSK’s RSV vaccine Arexvy recently gained EU approval for adults 18 and older.
29 January 2026
··
FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 today slips as pound jumps and gold hits $5,300; Marston’s dives

FTSE 100 fell 0.3% to 10,177.85 as a stronger pound hit overseas earners. Gold reached a record above $5,300 an ounce, boosting miners, while Marston’s dropped up to 16% on flat 17-week sales. Traders awaited the U.S. Fed’s policy decision later Wednesday. Oil prices eased but held near four-month highs after U.S. supply disruptions.
28 January 2026
········
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
···
1 2 3 4
Go toTop